Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD

Neurology. 2000 Aug 8;55(3):437-40. doi: 10.1212/wnl.55.3.437.

Abstract

Plasma homocysteine and cysteine levels were measured in 90 patients with PD with the MTHFR C677T (T/T) genotype. The authors found that the levels of homocysteine-a possible risk factor for vascular disease-were elevated by 60% in levodopa-treated patients with PD, with the most marked elevation occurring in patients with the T/T genotype. Cysteine levels in subjects with PD did not differ from levels in control subjects. In the T/T genotype patients, homocysteine and folate levels were inversely correlated. Increased homocysteine might be related to levodopa, MTHFR genotype, and folate in PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antiparkinson Agents / administration & dosage
  • Cysteine / blood
  • Female
  • Folic Acid / blood
  • Genotype
  • Homocysteine / blood*
  • Humans
  • Levodopa / administration & dosage
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Middle Aged
  • Oxidoreductases Acting on CH-NH Group Donors / genetics*
  • Parkinson Disease / blood*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / genetics*
  • Point Mutation*

Substances

  • Antiparkinson Agents
  • Homocysteine
  • Levodopa
  • Folic Acid
  • Oxidoreductases Acting on CH-NH Group Donors
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Cysteine